INTRODUCTION Worldwide incidence of anal squamous cell carcinoma (ASCC) is increasing.

1. Anal squamous cell carcinoma (ASCC) – Single centre observational study over 6 yearsEmmett S., Leung E., Acors N., Francombe J.Warwick Gastrointestinal UnitWarwick Hospital, Warwickshire, CV34 5BW • INTRODUCTION • Worldwide incidence of anal squamous cell carcinoma (ASCC) is increasing. • Limited data exist on predictors of treatment failure. • AIM • This study analyzed prognostic factors in ASCC over 6 years in a single centre covering 230,000 people • METHODS • Between August 2001 and 2007, all histologically confirmed ASCC patients were retrospectively selected. • Demographics, co-morbidities, TMN-staging, treatment modalities, local recurrence and mortality within a median 20-month follow-up (6-60 months) were assessed. • Chi2 testing was used to assess statistical significance. RESULTS • 23 patients were identified (age ranged 29-81, median 60; 13M:10F). • The incidence of ASCC remained static over the last 6 years. • The commonest presentations were perianal bleeding (56%) and proctalgia (30%). • There was no association between period prevalence and heavy smoking or excess alcohol consumption (p>0.05). • Recurrence and mortality rate were associated with advanced (T3 or T4) tumours at diagnosis (p<0.05). • CONCLUSIONS • Our period prevalence of ASCC is comparable with many centres previously reported. • There is no evidence to support increased incidence of ASCC. • Our current treatment modalities are effective, however, recurrence remains a concern which may necessitate intensive follow-up or post-adjuvant surgery. • With availability of Papanicolaou test, further study is needed to assess whether early diagnosis would reduce recurrence and mortality rate.